Loading
A phase 1/2 trial of Ibrutinib in diffuse large b-cell lymphoma, run by Novartis Pharmaceuticals, active and no longer recruiting.
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL is a phase 1/2 interventional study registered as NCT03960840 by Novartis Pharmaceuticals, with 217 participants enrolled, started 2019-06-26 and due to reach its primary completion in 2027-06-30. Interventions recorded: Rapcabtagene autoleucel single agent, Ibrutinib. Conditions listed: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ibrutinib, Diffuse large B-cell lymphoma, Small-molecule kinase inhibitors.
Shares Novartis, Small-molecule kinase inhibitors.
Shares Novartis, Small-molecule kinase inhibitors.
Shares Novartis, Diffuse large B-cell lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/